Lv1
80 积分 2024-07-22 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
18天前
已完结
原发性肝癌介入治疗研究现状及展望
20天前
已关闭
经桡动脉入路肝癌介入治疗综合管理中国专家共识(2024版)
20天前
已完结
Unraveling the multifaceted landscape of hepatocellular carcinoma evolution: From pivotal genetic drivers to therapeutic horizons
20天前
已关闭
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials
25天前
已完结
Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma
25天前
已完结
Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study
25天前
已完结
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
25天前
已完结
Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
25天前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
25天前
已完结
皖公网安备34019202002308
